Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Interdisciplinary Management of Colorectal Liver Metastases in the Era of...
share announcement

Interdisciplinary Management of Colorectal Liver Metastases in the Era of Precision Medicine

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (20 May 2023) | Viewed by 4682

Special Issue Editor

Prof. Dr. Hauke Lang

E-Mail Website
Guest Editor
Department of General-, Visceral- and Transplant Surgery, University Medical Center of the Johannes Gutenberg University, Langenbeckstrasse 1, D-55131 Mainz, Germany
Interests: CRLM; HCC; perihilar cholangiocarcinoma; intrahepatic cholangiocarcinoma; molecular profiling
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Colorectal liver metastases (CRLM) occur in nearly half of the patients with colorectal cancer and are the main cause of cancer-related death within this population. Although liver resection remains the mainstay of treatment, multidisciplinary management of CRLM, including the introduction of effective downsizing regimens and new surgical concepts, has improved the oncological outcome over recent years, resulting in long-term survival rates of up to 50-60% based on patient selection and prognostic factors. With the implementation of next-generation sequencing (NGS) of cancer-related genes and molecular profiling, another interesting and encouraging field of multimodal therapeutic and prognostic approaches has arisen. In fact, the most prominent and frequently analyzed mutations affect the RAS/RAF pathway (KRAS, NRAS, BRAF) as well as TP53 and PIK3CA and SMAD4. The aim of NGS is to facilitate the provision of individual oncologic precision medicine to each patient with CRLM and to increase their chance of long-term survival or even being cured. Nevertheless, there are several open questions concerning the limitations, the correct use in clinical daily routine, and the effectiveness and applicability of molecular biomarkers in patients with CRLM.

The present Special Issue aims to provide an update on current diagnostic and therapeutic strategies for CRLM, with special focus on surgical treatment embedded in multimodal treatment concepts including chemotherapy, local ablation and interventional treatment, external or internal radiotherapy as well as treatment-based molecular profiling.

Prof. Dr. Hauke Lang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • colorectal liver metastases
  • multimodal treatment
  • next-generation sequencing
  • molecular biology
  • chemotherapy
  • SIRT
  • TACE
  • liver resection

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 860 KiB  
Article
Safety of Early Bevacizumab Administration after Central Venous Port Placement for Patients with Colorectal Cancer
by Hirona Shigyo, Hiroyuki Suzuki, Toshimitsu Tanaka, Etsuko Moriyama, Yasutaka Shimotsuura, Sachiko Nagasu, Hideki Iwamoto, Yoshito Akagi, Kenta Murotani, Takumi Kawaguchi and Keisuke Miwa
Cancers 2023, 15(8), 2264; https://doi.org/10.3390/cancers15082264 - 12 Apr 2023
Cited by 3 | Viewed by 2360
Abstract
Bevacizumab (BEV) requires an adequate withdrawal period to avoid BEV-related complications during major surgery. However, the safety of BEV administration immediately after surgical placement of the central venous (CV) port, a minor surgery, is still unclear. This study aimed to investigate whether BEV [...] Read more.
Bevacizumab (BEV) requires an adequate withdrawal period to avoid BEV-related complications during major surgery. However, the safety of BEV administration immediately after surgical placement of the central venous (CV) port, a minor surgery, is still unclear. This study aimed to investigate whether BEV is safe when administered early after CV port placement. We retrospectively evaluated 184 patients with advanced colorectal cancer (CRC) treated with a BEV-containing regimen and divided them into two groups according to the interval between CV port implantation and chemotherapy initiation, with the early administration group being ≤7 days and late administration group being >7 days. Complications were then compared between the two groups. The early-administration group was significantly older and had a higher rate of colon cancer than the late-administration group. Overall, 24 (13%) patients developed CV port-related complications. Male sex was a risk factor for complications (odds ratio [OR], 3.154; 95% CI, 1.19–8.36). The two groups showed no significant difference in the frequency of complications (p = 0.84) or patient characteristics (after the inverse probability of treatment weighting, p = 0.537). In conclusion, the frequency of complications is not affected by the timing of BEV initiation after CV port implantation. Thus, early BEV administration after CV port placement is safe. Full article
(This article belongs to the Special Issue Interdisciplinary Management of Colorectal Liver Metastases in the Era of Precision Medicine)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 1554 KiB  
Review
The Role of Targeted Therapy in the Multi-Disciplinary Approach to Colorectal Liver Metastasis
by Samantha M. Ruff, Alexander H. Shannon and Timothy M. Pawlik
Cancers 2023, 15(13), 3513; https://doi.org/10.3390/cancers15133513 - 6 Jul 2023
Cited by 1 | Viewed by 1953
Abstract
Colorectal cancer (CRC) is the second most common cause of cancer-related mortality in the United States. Among newly diagnosed patients with CRC, 20% will present with metastatic disease and another 25% will develop metastases. The surgical resection of the primary tumor and metastatic [...] Read more.
Colorectal cancer (CRC) is the second most common cause of cancer-related mortality in the United States. Among newly diagnosed patients with CRC, 20% will present with metastatic disease and another 25% will develop metastases. The surgical resection of the primary tumor and metastatic disease sites confers the best chance at long-term survival. Unfortunately, many patients will recur after resection or present with unresectable disease. As such, metastatic CRC is commonly treated with a combination of surgery, systemic therapy, and/or liver-directed therapies. Despite best efforts, 5-year survival for unresectable metastatic CRC is only about 20%. CRC is a heterogeneous disease and the underlying genetic differences inform behavior, treatment strategy, and prognosis. Given the limitations of cytotoxic chemotherapy and the growing role of molecular profiling, research has focused on identifying and developing targeted therapies. We herein review how genetic profiling informs prognosis, crucial cell-signaling pathways that play a role in CRC carcinogenesis, and currently approved targeted therapies for metastatic CRC. Full article
(This article belongs to the Special Issue Interdisciplinary Management of Colorectal Liver Metastases in the Era of Precision Medicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop